Aarkstore - Tetrahydrofolate Dehydrogenase Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Tetrahydrofolate Dehydrogenase Inhibitors -Pipeline Insights, 2014 PowerPoint presentation | free to download - id: 6c0f09-MWVjZ



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Tetrahydrofolate Dehydrogenase Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Tetrahydrofolate Dehydrogenase Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Tetrahydrofolate Dehydrogenase Inhibitors. – PowerPoint PPT presentation

Number of Views:5

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Tetrahydrofolate Dehydrogenase Inhibitors -Pipeline Insights, 2014


1
Tetrahydrofolate Dehydrogenase Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/76034/tetrahydrofolate-dehydrogenase-inhibitors-
    pipeline-insights-2014

2
Summary
  • DelveInsights,Tetrahydrofolate Dehydrogenase
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Tetrahydrofolate Dehydrogenase
    Inhibitors. This report provides information on
    the therapeutic development based on the
    Tetrahydrofolate Dehydrogenase Inhibitors dealing
    with mechanism of action, comparative analysis at
    various stages covering Filed, Phase III, Phase
    II, Phase I, IND filed, Preclinical, Discovery
    and unknown stages, therapeutics assessment by
    monotherapy and combination products and molecule
    type drug information. The report also covers the
    companies information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts. Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases. Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action.

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Tetrahydrofolate
    Dehydrogenase Inhibitors The report provides
    pipeline products under drug profile section
    which includes product description, MOA,
    licensors collaborators, development partner
    and chemical information Coverage of the
    Tetrahydrofolate Dehydrogenase Inhibitors
    pipeline on the basis of target, MOA, route of
    administration, technology involved and molecule
    type The report reviews key players involved in
    the therapeutics development for Tetrahydrofolate
    Dehydrogenase Inhibitors and also provide company
    profiling The report also gives the information
    of dormant and discontinued pipeline
    projects  Pipeline products coverage based on
    various stages of development ranging from
    preregistration till discovery and undisclosed
    stages  Provides pipeline assessment by
    monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buy Complete MOA intelligence and
    complete understanding over therapeutics
    development for Tetrahydrofolate Dehydrogenase
    Inhibitors Identify the relationship between the
    drugs and use it for target finding, drug
    repurposing, and precision medicine. Devise
    corrective measures for pipeline projects by
    understanding Tetrahydrofolate Dehydrogenase
    Inhibitors pipeline depth and focus of Indication
    therapeutics  Developing strategic initiatives to
    support your drug development activities. Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and Scope Provides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies  Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipeline Gaining a Full Picture of the
    Competitive Landscape for Evidence based
    Decisions

7
Table of Content
  • Tetrahydrofolate Dehydrogenase Inhibitors
    Overview Tetrahydrofolate Dehydrogenase
    Inhibitors Disease Associated Tetrahydrofolate
    Dehydrogenase Inhibitors Pipeline
    Therapeutics Tetrahydrofolate Dehydrogenase
    Inhibitors Therapeutics under Development by
    Companies  Tetrahydrofolate Dehydrogenase
    Inhibitors Late Stage Products (Filed and Phase
    III) Comparative Analysis  Tetrahydrofolate
    Dehydrogenase Inhibitors Mid Clinical Stage
    Products (Phase II) Comparative
    Analysis  Tetrahydrofolate Dehydrogenase
    Inhibitors Early Clinical Stage Products (Phase I
    and IND Filed) Comparative Analysis  Tetrahydrofol
    ate Dehydrogenase Inhibitors Discovery and
    Pre-Clinical Stage Products  Comparative
    Analysis  Drug Candidate Profiles

8
Table of Content
  • Tetrahydrofolate Dehydrogenase Inhibitors
    Therapeutics Assessment  Assessment by
    Monotherapy Products  Assessment by Combination
    Products  Assessment by Route of
    Administration  Assessment by Molecule
    Type  Tetrahydrofolate Dehydrogenase Inhibitors
    Discontinued Products  Tetrahydrofolate
    Dehydrogenase Inhibitors Dormant
    Products Companies Involved in Therapeutics
    Development for Tetrahydrofolate Dehydrogenase
    Inhibitors  Appendix  Methodology  Contact
    Us  Disclaimer

9
List of Tables
  • Number of Products under Development for
    Tetrahydrofolate Dehydrogenase Inhibitors by
    Therapy Area, 2014 Number of Products under
    Development for Tetrahydrofolate Dehydrogenase
    Inhibitors, 2014 Number of Products under
    Development by Companies  Comparative Analysis by
    Late Clinical Stage Products (Filed and Phase
    III), 2014 Comparative Analysis Mid Clinical
    Stage Products (Phase II), 2014 Comparative
    Analysis Early Clinical Stage Products (Phase I
    and IND Filed), 2014 Comparative Analysis
    Discovery and Pre-Clinical Stage Products,
    2014 Drug Candidates Profiles

10
List of Tables
  • Tetrahydrofolate Dehydrogenase Inhibitors
    Assessment by Monotherapy Products  Tetrahydrofola
    te Dehydrogenase Inhibitors Assessment by
    Combination Products  Tetrahydrofolate
    Dehydrogenase Inhibitors Assessment by Route of
    Administration  Tetrahydrofolate Dehydrogenase
    Inhibitors Assessment by Stage and Route of
    Administration  Tetrahydrofolate Dehydrogenase
    Inhibitors Assessment by Molecule
    Type  Tetrahydrofolate Dehydrogenase Inhibitors
    Assessment by Stage and Molecule
    Type  Tetrahydrofolate Dehydrogenase Inhibitors
    Therapeutics Discontinued Products  Tetrahydrofola
    te Dehydrogenase Inhibitors Therapeutics Dormant
    Products Products under Development by Companies,
    2014

11
List of Figures
  • Number of Products under Development for
    Tetrahydrofolate Dehydrogenase Inhibitors by
    Therapy Area, 2014 Number of Products under
    Development for Tetrahydrofolate Dehydrogenase
    Inhibitors, 2014 Late Clinical Stage Products
    (Filed and Phase III), 2014 Mid Clinical Stage
    Products (Phase II), 2014 Early Clinical Stage
    Products (Phase I and IND Filed), 2014 Discovery
    and Pre-Clinical Stage Products,
    2014 Tetrahydrofolate Dehydrogenase Inhibitors
    Assessment by Monotherapy Products  Tetrahydrofola
    te Dehydrogenase Inhibitors Assessment by
    Combination Products  Tetrahydrofolate
    Dehydrogenase Inhibitors Assessment by Route of
    Administration  Tetrahydrofolate Dehydrogenase
    Inhibitors Assessment by Stage and Route of
    Administration  Tetrahydrofolate Dehydrogenase
    Inhibitors Assessment by Molecule
    Type  Tetrahydrofolate Dehydrogenase Inhibitors
    Assessment by Stage and Molecule Type

12
Related Reports
  • The Mobile Healthcare (mHealth) Bible 2014 -
    2020
  • Pregnancy Detection Kit Market in the US
    2015-2019
  • Global Prenatal and Newborn Genetic Testing
    Market 2015-2019
  • Global Knee Implant market 2015-2019
  • Global Isosorbide Market 2015-2019
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Tetrahydrofolate Dehydrogenase Inhibitors
    -Pipeline Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Tetrahydrofolate Dehydrogenase
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).

    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor, B-Wing,
Mahaavir Icon,  Plot No.- 89 90,
Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com